Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

Fig. 1

Patient accrual and correlative analysis summary. A total of 27 patients were accrued and received treatment on the study. Two of the patients’ on-treatment biopsy revealed HER2+ FISH-amplified tumor, and study treatment was terminated (patients were excluded from the efficacy analysis but included in the toxicity analysis). mRNA profiling was performed for 20 patients with NanoString PanCancer Pathways analysis and 11 patients for BC360™. FoundationOne ® genomic mutation profiles were available for 9 patients

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us